The Metastatic Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Metastatic Breast Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Breast Cancer Market.

Some of the key takeaways from the Metastatic Breast Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Metastatic Breast Cancer treatment therapies with a considerable amount of success over the years. 
• Metastatic Breast Cancer companies working in the treatment market are Phoenix Molecular Designs, Dantari, Inc., Daiichi Sankyo Co., Ltd., Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S., Jiangsu HengRui Medicine Co., Ltd., Genor Biopharma Co., Ltd, RemeGen, SynCore Biotechnology, Byondis B.V., Sichuan Baili Pharmaceutical Co., Ltd., Allarity Therapeutics, Jiangsu Hansoh Pharmaceutical Co., Ltd., Kind Pharmaceuticals LLC, Shanghai Miracogen Inc., and others, are developing therapies for the Metastatic Breast Cancer treatment 

• Emerging Metastatic Breast Cancer therapies in the different phases of clinical trials are PMD-026, DAN-222, Patritumab Deruxtecan, Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant, Disitamab Vedotin, EndoTAG®-1 (SB05), trastuzumab duocarmazine, GNC 035, Stenoparib (2X-121), HS-10342, AND019, MRG002, and others are expected to have a significant impact on the Metastatic Breast Cancer market in the coming years.  
• On May 04, 2022, Rhizen Pharmaceuticals AG revealed positive interim findings from an ongoing Phase 2 study of Tenalisib in individuals with locally advanced or metastatic breast cancer during the ESMO Breast Cancer Meeting held in Berlin, Germany, from May 3 to May 5, 2022. The results indicated that Tenalisib was well received and displayed promising initial effectiveness when used alone, demonstrating potential in managing both primary and secondary resistant mBC. The data obtained supports the continued advancement of Tenalisib for patients diagnosed with HR+ and HER2- MBC.
• In April 2022, Alphamab Oncology shared that findings from the phase II clinical investigation of the chemo-free combination of KN026 with KN046 (KN026-203) were presented at the AACR Annual Meeting 2022 as an E-poster. The study, as of August 10, 2021, enrolled 24 patients diagnosed with HER2-positive solid tumors other than breast or gastric cancer, who had previously undergone at least one systemic therapy. Among the enrolled patients, 20 were assessable for overall response, revealing an overall response rate (ORR) of 55.0%, a disease control rate (DCR) of 85.0%, and a 6-month progression-free survival (PFS) rate of 84.1%. Additionally, among the 11 evaluable patients with colorectal cancer (CRC), the ORR was 45.5%, while the DCR was 90.9%.
• In April 2022, Quantum Leap Healthcare Collaborative™ (Quantum Leap) and Ambrx Biopharma Inc. disclosed the adoption of Ambrx’s antibody-drug conjugate (ADC) ARX788 for a fresh investigational approach within the I-SPY 2.2 TRIAL, aiming to treat HER2-positive breast cancer in the neoadjuvant context. Under the sponsorship of Quantum Leap, the I-SPY 2.2 TRIAL serves as a continuation of the I-SPY 2 TRIAL, intending to tailor treatments for individual patients to maximize their clinical outcomes.
• In March 2022, TYME Technologies, Inc. unveiled the release of a poster abstract titled “SM-88, D/L-alpha-metyrosine, as a groundbreaking anti-cancer treatment in estrogen receptor-positive breast cancer.” This abstract, submitted by researchers affiliated with Georgetown University, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 held in New Orleans, LA. In a prior announcement in September 2021, TYME Technologies, Inc. had disclosed the dosing of the first patient in the Phase II OASIS trial. This trial, conducted by Georgetown University (NCT04720664) at various MedStar Health hospitals (Georgetown’s academic clinical partner), focuses on patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer who had previously undergone a CDK4/6 inhibitor regimen.
• In February 2022, Phoenix Molecular Designs (PhoenixMD) declared the conclusion of patient enrollment and administration of PMD-026 in their Phase 1b clinical trial, focusing on monotherapy. This accomplishment in concluding patient enrollment within the Phase 1/1b trial signifies a significant milestone for PhoenixMD as they progress with PMD-026 towards Phase 2 trials that explore its combination therapy potential for treating triple-negative breast cancer (TNBC) and hormone-positive breast cancer.
• In December 2021, Arvinas, Inc. and Pfizer Inc. provided a progress update on the Phase 1 dose-escalation findings concerning ARV-471, an innovative PROTAC® estrogen receptor (ER) degrader. This compound is under joint development for addressing individuals diagnosed with locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-).
• In August 2021, Seagen Inc. and RemeGen Co., Ltd. revealed their agreement, establishing an exclusive global licensing deal for the development and commercialization of disitamab vedotin, an innovative HER2-targeted Antibody-Drug Conjugate (ADC).

Metastatic Breast Cancer Overview

When breast cancer spreads to another area of the body, usually the brain, liver, lungs, or bones, it is referred to as metastatic breast cancer, also known as stage IV breast cancer. Many months or years after the initial diagnosis and treatment, breast cancer may recur in a different place of the body.

Get a Free Sample PDF Report to know more about Metastatic Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/metastatic-breast-cancer-pipeline-insight

Emerging Metastatic Breast Cancer Drugs Under Different Phases of Clinical Development Include:

• PMD-026: Phoenix Molecular Designs
• DAN-222: Dantari, Inc.
• Patritumab Deruxtecan: Daiichi Sankyo Co., Ltd.
• Tenalisib: Rhizen Pharmaceuticals SA
• OP-1250: Olema Oncology
• Eftilagimod alpha: Immutep S.A.S.
• SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
• GB491+ Fulvestrant : Genor Biopharma Co., Ltd
• Disitamab Vedotin: RemeGen
• EndoTAG®-1 (SB05): SynCore Biotechnology
• trastuzumab duocarmazine: Byondis B.V.
• GNC 035: Sichuan Baili Pharmaceutical Co., Ltd.
• Stenoparib (2X-121): Allarity Therapeutics
• HS-10342: Jiangsu Hansoh Pharmaceutical Co., Ltd.
• AND019: Kind Pharmaceuticals LLC
• MRG002: Shanghai Miracogen Inc.

Metastatic Breast Cancer Route of Administration

Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Metastatic Breast Cancer Molecule Type

Metastatic Breast Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Metastatic Breast Cancer Pipeline Therapeutics Assessment

• Metastatic Breast Cancer Assessment by Product Type
• Metastatic Breast Cancer By Stage and Product Type
• Metastatic Breast Cancer Assessment by Route of Administration
• Metastatic Breast Cancer By Stage and Route of Administration
• Metastatic Breast Cancer Assessment by Molecule Type
• Metastatic Breast Cancer by Stage and Molecule Type

DelveInsight’s Metastatic Breast Cancer Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Metastatic Breast Cancer product details are provided in the report. Download the Metastatic Breast Cancer pipeline report to learn more about the emerging Metastatic Breast Cancer therapies

Some of the key companies in the Metastatic Breast Cancer Therapeutics Market include:

Key companies developing therapies for Metastatic Breast Cancer are – RemeGen, SynCore Biotechnology, Allarity Therapeutics, Eisai Inc., Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical, and others.

Metastatic Breast Cancer Pipeline Analysis:

The Metastatic Breast Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Breast Cancer Treatment.
• Metastatic Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Metastatic Breast Cancer drugs and therapies

Metastatic Breast Cancer Pipeline Market Drivers

• Increasing prevalence of breast cancer, launch of several diagnostic and screening programs are some of the important factors that are fueling the Metastatic Breast Cancer Market.

Metastatic Breast Cancer Pipeline Market Barriers 

• However, high cost associated with the treatment, several side effects associated with the use of breast cancer therapeutics and other factors are creating obstacles in the Metastatic Breast Cancer Market growth.

Scope of Metastatic Breast Cancer Pipeline Drug Insight    

• Coverage: Global
• Key Metastatic Breast Cancer Companies: Phoenix Molecular Designs, Dantari, Inc., Daiichi Sankyo Co., Ltd., Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S., Jiangsu HengRui Medicine Co., Ltd., Genor Biopharma Co., Ltd, RemeGen, SynCore Biotechnology, Byondis B.V., Sichuan Baili Pharmaceutical Co., Ltd., Allarity Therapeutics, Jiangsu Hansoh Pharmaceutical Co., Ltd., Kind Pharmaceuticals LLC, Shanghai Miracogen Inc., and others
• Key Metastatic Breast Cancer Therapies: PMD-026, DAN-222, Patritumab Deruxtecan, Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant, Disitamab Vedotin, EndoTAG®-1 (SB05), trastuzumab duocarmazine, GNC 035, Stenoparib (2X-121), HS-10342, AND019, MRG002, and others
• Metastatic Breast Cancer Therapeutic Assessment: Metastatic Breast Cancer current marketed and Metastatic Breast Cancer emerging therapies
• Metastatic Breast Cancer Market Dynamics: Metastatic Breast Cancer market drivers and Metastatic Breast Cancer market barriers 

Request for Sample PDF Report for Metastatic Breast Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Metastatic Breast Cancer Report Introduction

2. Metastatic Breast Cancer Executive Summary

3. Metastatic Breast Cancer Overview

4. Metastatic Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. Metastatic Breast Cancer Pipeline Therapeutics

6. Metastatic Breast Cancer Late Stage Products (Phase II/III)

7. Metastatic Breast Cancer Mid Stage Products (Phase II)

8. Metastatic Breast Cancer Early Stage Products (Phase I)

9. Metastatic Breast Cancer Preclinical Stage Products

10. Metastatic Breast Cancer Therapeutics Assessment

11. Metastatic Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Metastatic Breast Cancer Key Companies

14. Metastatic Breast Cancer Key Products

15. Metastatic Breast Cancer Unmet Needs

16 . Metastatic Breast Cancer Market Drivers and Barriers

17. Metastatic Breast Cancer Future Perspectives and Conclusion

18. Metastatic Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services